LAI Care Study

Relapse and rehospitalization rates are inordinately high in schizophrenia (even in early phase of illness). Long-acting injectable (LAI) formulations of antipsychotic medications have been consistently shown to significantly reduce these risks in both early and later phase illness. Despite these data, these formulations are substantially underutilized. There are many barriers to their widespread use, but having options which are easier to use and more acceptable to clinicians, patients and families could be advantageous.

LAI-CARE is an interactive educational web resource about long-acting injectable antipsychotics (LAIs) for healthcare professionals, people living with schizophrenia, and caregivers. The goal of the tool is to help these groups communicate with one another about LAIs and thereby address barriers to the acceptance of LAIs. The tool does not promote any specific product over any other, nor does it mention any branded products by name. The website will neither collect nor store any data from users.

Investigators

Principal Investigator, ORI
Project Start Date

06/06/2025

Project End Date

06/05/2026

Funding Agency

Teva

Current Status

Active and recruiting